BI-78D3
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 530628

CAS#: 883065-90-5

Description: BI-78D3, also known as JNK Inhibitor X, is a potent JNK inhibitor. BI-78D3 dose-dependently inhibits the phosphorylation of JNK substrates both in vitro and in cell. BI-78D3 not only blocks JNK dependent Con A-induced liver damage but also restores insulin sensitivity in mouse models of type 2 diabetes.


Chemical Structure

img
BI-78D3
CAS# 883065-90-5

Theoretical Analysis

MedKoo Cat#: 530628
Name: BI-78D3
CAS#: 883065-90-5
Chemical Formula: C13H9N5O5S2
Exact Mass: 379.0045
Molecular Weight: 379.365
Elemental Analysis: C, 41.16; H, 2.39; N, 18.46; O, 21.09; S, 16.90

Price and Availability

Size Price Availability Quantity
10.0mg USD 150.0 2 weeks
25.0mg USD 250.0 2 weeks
50.0mg USD 450.0 2 weeks
100.0mg USD 650.0 2 weeks
200.0mg USD 950.0 2 weeks
500.0mg USD 1650.0 2 weeks
1.0g USD 2450.0 2 weeks
2.0g USD 3850.0 2 weeks
5.0g USD 5850.0 2 weeks
Click to view more sizes and prices
Bulk inquiry

Synonym: JNK Inhibitor X; BI-78D3; BI78D3; BI 78D3.

IUPAC/Chemical Name: 4-(2,3-dihydro-1,4-benzodioxin-6-yl)-2,4-dihydro-5-[(5-nitro-2-thiazolyl)thio]-3H-1,2,4-triazol-3-one

InChi Key: QFRLDZGQEZCCJZ-UHFFFAOYSA-N

InChi Code: InChI=1S/C13H9N5O5S2/c19-11-15-16-12(25-13-14-6-10(24-13)18(20)21)17(11)7-1-2-8-9(5-7)23-4-3-22-8/h1-2,5-6H,3-4H2,(H,15,19)

SMILES Code: O=C1NN=C(SC2=NC=C([N+]([O-])=O)S2)N1C3=CC=C(OCCO4)C4=C3

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Product Data:

Biological target: BI-78D3 inhibits the JNK kinase activity with an IC50 of 280 nM.
In vitro activity: As the ERK pathway regulates cell survival and proliferation1, the proliferation potential of cells following incubation with BI-78D3, with drug washout, was evaluated by monitoring their approach to confluence. Dose-dependent suppression of cell growth (IC50 ~ 3.5 µM) was noted when measured over 90 h (Fig. 4d). A similar treatment abrogated the formation of anchorage-dependent and anchorage-independent colonies (Fig. 4e). Cell cycle analysis revealed that treatment with BI-78D3 (6 µM), followed by washout for 24 and 48 h induced G1 arrest (Supplementary Fig. 17). Annexin V (Fig. 4f) and caspase3/7 assays (Fig. 4g) revealed significant dose-dependent induction of apoptosis 72 h after treatment, which is also evidenced by a significant induction of a sub-G1 population (Supplementary Fig. 18). Similar results were observed when BI-78D3 was not washed out. Reference: Nat Commun. 2019 Nov 19;10(1):5232. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6863825/
In vivo activity: The effect of BI-78D3 on the growth of a BRAF-mutant xenograft model established from the human melanoma cell line A375 was evaluated. Inbred, athymic nude mice were injected with 1 × 106 A375 cells into the right flank. When tumors reached an average volume of 150 mm3, mice were randomized into two groups of ten mice each. One group was treated daily with an intraperitoneal injection of vehicle (2.5% ethanol, 5% Tween-80, 1× PBS), and the other group with 15 mg kg−1 BI-78D3 suspended in the vehicle. Tumor volumes were measured daily until tumors reached a maximum diameter of 1 cm. The tumor measurements of these mice were analyzed for tumor growth comparison (Fig. 5a) where BI-78D3 (15 mg kg−1 daily) caused potent tumor growth suppression after 10 days of treatment. BI-78D3 was tolerated by the mice, as measured by morbidity, lethality, and loss in body weight (Supplementary Fig. 23). Reference: Nat Commun. 2019 Nov 19;10(1):5232. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6863825/

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMF 33.0 86.99
DMSO 67.74 178.56
DMSO:PBS (pH 7.2) (1:1) 0.5 177.93
Ethanol 1.4 3.69

Preparing Stock Solutions

The following data is based on the product molecular weight 379.365 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Kaoud TS, Johnson WH, Ebelt ND, Piserchio A, Zamora-Olivares D, Van Ravenstein SX, Pridgen JR, Edupuganti R, Sammons R, Cano M, Warthaka M, Harger M, Tavares CDJ, Park J, Radwan MF, Ren P, Anslyn EV, Tsai KY, Ghose R, Dalby KN. Modulating multi-functional ERK complexes by covalent targeting of a recruitment site in vivo. Nat Commun. 2019 Nov 19;10(1):5232. doi: 10.1038/s41467-019-12996-8. PMID: 31745079; PMCID: PMC6863825.
In vitro protocol: 1. Kaoud TS, Johnson WH, Ebelt ND, Piserchio A, Zamora-Olivares D, Van Ravenstein SX, Pridgen JR, Edupuganti R, Sammons R, Cano M, Warthaka M, Harger M, Tavares CDJ, Park J, Radwan MF, Ren P, Anslyn EV, Tsai KY, Ghose R, Dalby KN. Modulating multi-functional ERK complexes by covalent targeting of a recruitment site in vivo. Nat Commun. 2019 Nov 19;10(1):5232. doi: 10.1038/s41467-019-12996-8. PMID: 31745079; PMCID: PMC6863825.
In vivo protocol: 1. Kaoud TS, Johnson WH, Ebelt ND, Piserchio A, Zamora-Olivares D, Van Ravenstein SX, Pridgen JR, Edupuganti R, Sammons R, Cano M, Warthaka M, Harger M, Tavares CDJ, Park J, Radwan MF, Ren P, Anslyn EV, Tsai KY, Ghose R, Dalby KN. Modulating multi-functional ERK complexes by covalent targeting of a recruitment site in vivo. Nat Commun. 2019 Nov 19;10(1):5232. doi: 10.1038/s41467-019-12996-8. PMID: 31745079; PMCID: PMC6863825.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Hein TW, Xu W, Xu X, Kuo L. Acute and Chronic Hyperglycemia Elicit JIP1/JNK-Mediated Endothelial Vasodilator Dysfunction of Retinal Arterioles. Invest Ophthalmol Vis Sci. 2016 Aug 1;57(10):4333-40. doi: 10.1167/iovs.16-19990. PubMed PMID: 27556216; PubMed Central PMCID: PMC5015966.

2: Alaseem AM, Madiraju P, Aldebeyan SA, Noorwali H, Antoniou J, Mwale F. Naproxen induces type X collagen expression in human bone-marrow-derived mesenchymal stem cells through the upregulation of 5-lipoxygenase. Tissue Eng Part A. 2015 Jan;21(1-2):234-45. doi: 10.1089/ten.TEA.2014.0148. Epub 2014 Oct 23. PubMed PMID: 25091567; PubMed Central PMCID: PMC4292866.

3: Posthumadeboer J, van Egmond PW, Helder MN, de Menezes RX, Cleton-Jansen AM, Beliën JA, Verheul HM, van Royen BJ, Kaspers GJ, van Beusechem VW. Targeting JNK-interacting-protein-1 (JIP1) sensitises osteosarcoma to doxorubicin. Oncotarget. 2012 Oct;3(10):1169-81. PubMed PMID: 23045411; PubMed Central PMCID: PMC3717953.

4: Strittmatter F, Walther S, Gratzke C, Göttinger J, Beckmann C, Roosen A, Schlenker B, Hedlund P, Andersson KE, Stief CG, Hennenberg M. Inhibition of adrenergic human prostate smooth muscle contraction by the inhibitors of c-Jun N-terminal kinase, SP600125 and BI-78D3. Br J Pharmacol. 2012 Jul;166(6):1926-35. doi: 10.1111/j.1476-5381.2012.01919.x. PubMed PMID: 22364229; PubMed Central PMCID: PMC3402815.

5: Stebbins JL, De SK, Machleidt T, Becattini B, Vazquez J, Kuntzen C, Chen LH, Cellitti JF, Riel-Mehan M, Emdadi A, Solinas G, Karin M, Pellecchia M. Identification of a new JNK inhibitor targeting the JNK-JIP interaction site. Proc Natl Acad Sci U S A. 2008 Oct 28;105(43):16809-13. doi: 10.1073/pnas.0805677105. Epub 2008 Oct 15. PubMed PMID: 18922779; PubMed Central PMCID: PMC2567907.

BI-78D3

10.0mg / USD 150.0


Additional Information

JNK is a stress-activated protein kinase that modulates pathways implicated in a variety of disease states. JNK-interacting protein-1 (JIP1) is a scaffolding protein that enhances JNK signaling by creating a proximity effect between JNK and upstream kinases. A minimal peptide region derived from JIP1 is able to inhibit JNK activity both in vitro and in cell.